Syndax製藥 SNDX 深 滬
等待開盤 09-03 09:30:00 美东时间
16.12
-0.210
-1.29%
華盛通- 最 高16.885
- 今 開16.50
- 成交量 180.24万股
- 最 低 15.94
- 昨 收 16.33
- 總市值 13.87亿
- 52周最高 22.50
- 市盈率 靜 --
- 換手率 2.09%
- 52周最低 8.58
- 委 比 67.92%
- 總股本 8604.74万
- 歷史最高 29.86
- 量 比 0.70
- 振 幅 5.79%
- 歷史最低 3.39
- 每 手 1
- 風險率 2.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅345.51%！BTIG上调Syndax Pharmaceuticals目标价至56美元，维持"买入"评级
今日重点评级关注：BTIG：维持Syndax Pharmaceuticals"买入"评级，目标价从43美元升至56美元；花旗：维持Syndax Pharmaceuticals"买入"评级，目标价从46美元升至51美元
08-06 09:30
Syndax jumps after Q2 beat; Citi issues upside catalyst watch
Syndax Pharmaceuticals (NASDAQ:SNDX) added ~21% in the premarket on Tuesday after the cancer drugmaker reported better-than-expected Q2 2025 financials, prompting Citi to issue a 90-day upside catalys...
08-06 01:20
BTIG Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $56
BTIG analyst Justin Zelin maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $43 to $56.
08-06 00:29
Syndax Pharmaceuticals Q2 EPS $(0.83) Beats $(1.00) Estimate, Sales $37.958M Beat $26.780M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.00) by 17.33 percent. This is a 3.75 percent decrease over losses of $(0.80) per share
08-05 04:04
Here are the major earnings after the close Monday
Major earnings expected after the bell on Monday include: Palantir Technologies (PLTR) Simon Property Group (SPG) MercadoLibre (MELI) ONEOK (OKE) Vertex Pharmaceuticals Incorporated (VRTX) Other earni...
08-04 22:00
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
Syndax Pharmaceuticals's Earnings: A Preview
Syndax Pharmaceuticals (NASDAQ:SNDX) is gearing up to announce its quarterly ea...
08-02 05:04
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
Syndax Pharmaceuticals will report its Q2 2025 financial results and provide a business update on August 4, 2025. Management will host a conference call and live webcast at 4:30 p.m. ET, accessible via the company's website or dial-in numbers. A replay will be available 24 hours after the call. The company, focused on innovative cancer therapies, highlights its FDA-approved treatments, Revuforj® and Niktimvo™, and ongoing clinical trials. For mor...
07-28 11:00
Goldman Sachs Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $18
Goldman Sachs analyst Corinne Johnson initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $18.
07-10 20:51
William Meury Resigns from Syndax Pharmaceuticals Board
An update from Syndax Pharmaceuticals ( ($SNDX) ) is now available. On June 24,...
06-26 21:17
